期刊文献+

拉米夫定联合血浆置换治疗慢性乙型重型肝炎

Effect of Lamivudine Combined with Plasmaexchange in Treatment of Chronic Fulminant Hapatitis B
下载PDF
导出
摘要 目的:观察拉米夫定联合血浆置换治疗慢性乙型重型肝炎的疗效。方法:将48例慢性乙型重型肝炎患者随机分为对照组(22例),给予内科综合及血浆置换治疗;治疗组(26例),在此基础上加用拉米夫定,比较两组临床症状、TB(总胆红素)、PTA(凝血酶原活动度)、ALB及HBV-DNA含量。结果:治疗组在改善TB、PTA及提高治疗有效率、HBV-DNA阴转率方面较对照组差异有显著性(P<0.05)。结论:拉米夫定在血浆置换等的治疗基础上有可能进一步提高慢性乙型重型肝炎患者的治疗效果。 Objective : To study the effect of lamivudine combined with plasmaexchange in the treatment of chronic fulminant hapatitis B. Method: 48 patients with chronic fulminant hepatitis B were randomly divided into two groups. The therapy group was given lamivudine, based on plasmaexchange and other general treatment, while the controlled group was given the same treatment without lamivudine. And the main symptoms, TB, PTA, ALB and HBVDNA were observed and checked after treatment. Result: Significant differences were found between the two groups in the TB and PTA changes, HBVDNA loss and effective ratios. Conclusion: Lamivudine can improve the effects further bassed on the plasmaexchange treatment of chronic fulminant hepatitis B.
出处 《药物流行病学杂志》 CAS 2009年第2期88-90,共3页 Chinese Journal of Pharmacoepidemiology
关键词 乙型肝炎/重型 慢性 拉米夫定 血浆置换 Chronic fulminant Hapatitis B Lamivudine Plasmaexehange
  • 相关文献

参考文献6

二级参考文献23

  • 1拉米夫定临床应用专家组,万谟彬.2004年拉米夫定临床应用专家共识[J].中华传染病杂志,2004,22(4):283-287. 被引量:89
  • 2万谟彬.《2004年拉米夫定临床应用专家共识》解读[J].中华传染病杂志,2005,23(1):67-69. 被引量:8
  • 3Yao F, Terrault N, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology, 2001,34:411-416.
  • 4Yun-Fan Liaw, Joseph J. Y. Sung, Wan Cheng Chow, et al.Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease. N Engl J Med 2004;351 :1521-1531.
  • 5Hom X, Little NR, Gardner SD, et al. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J, 2004, 23: 441-445.
  • 6Patrick Marcellin, George K.K. Lau, Ferruccio Bonino,et al.Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med, 2004,351:1206-1217.
  • 7Lau GKK, Teetha Piratvisuth, Kang Xian Luo, et al.Peginterferon alpha-2a(40kDa) (PEGASYS(r)) monotherapy in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large , multinational study. Hepatology ,2004,40(Suppl 1) :171A.
  • 8Villeneuve JP,Condreay LD,Willems B,et al.Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.Hepatology,2000,31:207 -210.
  • 9Yao FY,Terrault NA,Freise C,et al.Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:a comparative study using a matched,untreated cohort.Hepatology,2001,34:411-416.
  • 10Lok AS,McMahon BJ.Chronic hepatitis B[].Hepatology.2001

共引文献14082

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部